Glucagon-like peptide-1 (GLP-1)
Glucagon-like peptide-1 (GLP-1) is a peptide hormone with important roles in glucose homeostasis and energy balance.
Glucagon-like peptide-1 (GLP-1) is a peptide hormone with important roles in glucose homeostasis and energy balance. It is produced primarily by enteroendocrine L-cells in the intestine and acts as an incretin, meaning it enhances glucose-dependent insulin secretion after nutrient intake. In biomedical research and therapeutics, GLP-1 is widely studied for its metabolic effects, including regulation of insulin secretion, appetite, and glycemic control in type 2 diabetes.
A key feature of GLP-1 biology is its rapid inactivation by Dipeptidyl peptidase 4 (DPP-4) (DPP4), which limits its circulating activity. Because of this, many studies focus on either increasing endogenous GLP-1 secretion or preventing its degradation. GLP-1 is therefore relevant not only as a hormone but also as a therapeutic target and biomarker in metabolic disease, obesity, and related cardiometabolic conditions.
Where the papers sit
9 papers from the last 6 months study Glucagon-like peptide-1 (GLP-1) directly · updated from PubMed 3 Oct 2026
Study type 1 clinical trial · 4 observational · 3 human data · 1 preclinical
Themes one subject · 1 new direction
Those 9 are all about one subject.
-
GLP-1 Biology and Therapeutics
GLP-1 biology is being linked to gastrointestinal motility, metabolic control, bone remodeling, brain metabolism and inflammation. Therapeutic design is moving toward metabolically stable triple-receptor agonists and receptor-guided PROTAC delivery. Clinical and observational work continues to examine delayed small-bowel transit, feeding intolerance and weight loss after bariatric procedures. Preclinical studies highlight HIF-2-AKT signaling in bone, effects on ulcerative colitis and diabetes, and possible tissue-specific actions, but no single direction dominates.
GLP-1 is repurposed as a receptor-guided intracellular delivery vehicle for targeted protein degradation
The multicomponent-stapled GLP-1 agent in GLP-1 receptor-positive cells was not used chiefly as a metabolic signaling agonist; instead, it retained receptor agonism while delivering a BRD4-directed PROTAC into cells and inducing selective intracellular BRD4 degradation. This gives GLP-1 a carrier and cell-selective drug-entry role, extending it beyond the set’s uses as a metabolic or tissue-signaling mediator and establishing a platform for receptor-guided protein degradation 42283322Jun.
Papers
The 9 papers from the last 6 months that study Glucagon-like peptide-1 (GLP-1) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
GLP-1 Biology and Therapeutics (9)
- PMID 41962608
- PMID 41940860
- Elevated plasma glucagon-like Peptide-1 levels are associated with enteral feeding intolerance in traumatic brain injury. Clinical nutrition (Edinburgh, Scotland) · 3 Aug 2026 PMID 42546448
- Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity. Journal of computer-aided molecular design · 30 Jul 2026 PMID 42530676
- Association between GLP-1-based therapy and small-bowel transit time during capsule endoscopy: a prospective, multicentre, observational study. BMJ open gastroenterology · 15 Jul 2026 PMID 42457308
- GLP-1 regulates osteo-adipogenic fate of BMSCs via HIF-2-AKT signaling and supports trabecular bone in glucocorticoid-induced osteoporosis. Stem cell reports · 9 Jul 2026 PMID 42425087
- Multicomponent Stapling of Glucagon-Like Peptide-1 Enables Receptor-Guided PROTAC Delivery. Angewandte Chemie (International ed. in English) · 12 Jun 2026 PMID 42283322
- Incidence and Predictors of Suboptimal Early Weight Loss after Bariatric Procedures. Obesity surgery · 22 May 2026 PMID 42174245
- Insights from changes in NDEV biomarkers of metabolism: effects of PPARγ and GLP1 receptor agonists on brain metabolism. The Journal of clinical endocrinology and metabolism · 17 Apr 2026 PMID 41992726
By study type
Clinical trials (1)
- Insights from changes in NDEV biomarkers of metabolism: effects of PPARγ and GLP1 receptor agonists on brain metabolism. The Journal of clinical endocrinology and metabolism · 17 Apr 2026 PMID 41992726
Observational studies and case reports (4)
- Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ case reports · 7 Oct 2026 PMID 42843917
- Elevated plasma glucagon-like Peptide-1 levels are associated with enteral feeding intolerance in traumatic brain injury. Clinical nutrition (Edinburgh, Scotland) · 3 Aug 2026 PMID 42546448
- Association between GLP-1-based therapy and small-bowel transit time during capsule endoscopy: a prospective, multicentre, observational study. BMJ open gastroenterology · 15 Jul 2026 PMID 42457308
- Incidence and Predictors of Suboptimal Early Weight Loss after Bariatric Procedures. Obesity surgery · 22 May 2026 PMID 42174245
Human data, design not indexed (3)
- Bone marrow responses to GLP-1 and GIP infusion under hyperglycaemic conditions. European journal of endocrinology · 19 Sept 2026 PMID 42762476
- Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity. Journal of computer-aided molecular design · 30 Jul 2026 PMID 42530676
- Multicomponent Stapling of Glucagon-Like Peptide-1 Enables Receptor-Guided PROTAC Delivery. Angewandte Chemie (International ed. in English) · 12 Jun 2026 PMID 42283322
Preclinical: animal, cell and lab studies (1)
- GLP-1 regulates osteo-adipogenic fate of BMSCs via HIF-2-AKT signaling and supports trabecular bone in glucocorticoid-induced osteoporosis. Stem cell reports · 9 Jul 2026 PMID 42425087
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-07-16. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.